TTUHSC School of Medicine
Internal Medicine

Internal Medicine

Faculty Listing » Oncology


Everardo Cobos

Everardo Cobos, MD

Professor
Associate Dean for Oncology Programs/ Division Chief: Oncology/Hematology

Office: 806-743-3155
Email: everardo.cobos@ttuhsc.edu

Patient Appointments:
806-775-8600
Clinic Location:
Southwest Cancer and Research Center 602 Indiana

Return to Faculty Listing go

Education:

  • Fellowship: Letterman Army Medical Center San Francisco, 1988
  • Residency: Letterman Army Medical Center San Francisco, 1985
  • Medical School: University of Texas San Antonio, M.D., 1981
  • Undergraduate School: University of Texas El Paso, B.S., 1977

Publications:

  • Plasma cell granuloma: a case report of multiple lesions in the lung and review of the literature. Am J Med Sci. 2007 Nov;334(5):402-6.
  • Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clin Appl Thromb Hemost. 2007 Oct; 13(4):443-8.
  • Biological Treatment for Liver Tumor and New Potential Biomarkers. Dig Dis Sci. 2007 Aug 22.
  • The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies.J. Laparoendosc Adv Surg Tech A. 2007 Jun; 17(3):282-4.
  • Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol.2007 May-Aug; 26(3-4): 197-222.
  • Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol.2007 Jun;15(2):134-9.
  • A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Spl7. J Immunol Methods.2007 April 10;321(1): 86-93.
  • Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med. Jan23; 5 (1):3 2007.
  • Comparison of High Dose VS. Low Dose G-CSF For Peripheral Blood Stem Cell Mobilization: Analysis Of a Case Control. Series.Abstract #0505. Haematologica / the hematology journal | 2007; 92(s1)
  • Effect of palifermin On the Incidence Of Mucositis, Hospital Stay, Acute GVHD and Total Parenteral Nutrition in Patients Undergoing Stem Cell Transplantation. Abstract #1220. Haematologica/the hematology journal | 2007; 92(s1)
  • Increased Age, Male Gender, and Cirrhosis, but Not Steatosis or a Positive Viral Serology, Negatively Impact the Life Expectancy of Patients who Undergo Liver Biopsy. Dig Dis Sci, 52, 2276-2281, 2007. IF 1.448
  • Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med. 5 (1):3, Jan 2007
  • A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Spl7. J Immunol Methods. 321(1): 86-93, Apr 2007.
  • Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol. 15(2):134-9, Jun 2007.
  • Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials. Int Rev Immunol. 26(3-4): 197-222, May-Aug 2007.
  • The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J. Laparoendosc Adv Surg Tech A. 17(3):282-4, Jun 2007.
  • Biological Treatment for Liver Tumor and New Potential Biomarkers. Dig Dis Sci, Aug2007.
  • Acquired hemophilia: a case report of 2 patients with acquired factor VIII inhibitor treated with rituximab plus a short course of steroid and review of the literature. Clin Appl Thromb Hemost. 13(4):443-8, Oct 2007.
  • Plasma cell granuloma: a case report of multiple lesions in the lung and review of the literature. Am J Med Sci. 334(5):402-6, Nov 2007.
  • AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 140(4);465-8, Feb 2008.
  • The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med. 2;6:15, Apr 2008.
  • Sperm fibrous sheath proteins: a potential new class of target antigens for ruse in human therapeutic cancer vaccines. Cancer Immun. 24;8:8, Apr 2008.
  • Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis. 29(9):1717-24. Sep 2008.
  • A therapeutic dose of FK506 does not affect collagen turnover pathways in healthy human gingival firoblasts. Transplant Proc. 40(5):1419-24, Jun 2008.
  • Sperm protein 17 is a suitable target for adoptive T-cell based immunotherapy in human ovarian cancer. J Immunother. 31(8):693-703, Oct 2008.
  • Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med. 5;6:56, Oct 2008.
  • rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol. 21(4):435-42, Dec 2008.
  • Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol. Apr;8(4):395-8, 2009
  • Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med. 15;7(1):61, July 2009.
  • Antibody microarray analysis of serum glycans in esophageal squamous cell carcinoma cases and controls. Proteomics-Clinical Applications, 3:923–931, 2009.
  • Curcumin modulates eukaryotic initiation factors in human lung adenocarcinoma epithelial cells. Mol Biol Rep. 2009, PMID: 19826913.
  • Glioma-astrocyte interaction modifies the astrocyte phenotype in a co-culture experimental model. Oncol Rep. 22(6);1349-56, 2009.
  • Abl Interactor 1 Regulates Src-Id1-Matrix Metalloproteinase 9 Axis and is required for invadopodia formation, extracellular matrix degradation, and tumor growth of human breast cancer cells. Carcinogenesis, 2009.
  • Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra/extracellular SPARC expression. Pancreatology; 10(5):542-52. 2010.
  • A practical model for psychosocial care. Journal of Oncology Practice; 6(1): 34-36, 2010.
  • 4-(methylnitro-samino)-1-(3-pyridyl)-1-butanone induces CRM1-dependent p53 nuclear accumulation in human bronchial epithelial cells. Toxicol Sci. ;116(1):206-15, Jul 2010.
  • Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One. 12;5(5):e10471, May 2010.
  • p53-dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol, Aug 2010.
  • An update on hematological malignancies. Tex Med. 1;106(9):59-63, Sep 2010.
  • Genistein and hematological malignancies. Cancer Lett. 1;296(1):1-8. 2010 May 23, Oct 2010.
  • Nanotechnology and human health: risks and benefits. J Appl Toxicol. 2010 Nov;30(8):730-44.
  • Ropporin: a Novel Cancer Testis Antigen in Multiple Myeloma. (accepted) Journal of Immunotherapy. 2011.
  • Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. The Prostate. 2012 Jan;72(1):12-23
  • Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. (accepted) Immunol Rev, May, 2011.
  • Prospects and Challenges for Immunotherapy of Ovarian Cancer – What Can We Learn from the Tumor Microenvironment? (accepted) Immunol Rev, May, 2011. (Editorial)
  • Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer. (accepted) Immunol Rev, May, 2011.
  • Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol. 2012 Feb;31(1):3-21
  • Application of Vitamin D and Derivatives in Hematological Malignancies. (submitted). 2011.
  • Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol. 2012 Apr;226(5):713-22
  • Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol. 2012 Feb;31(1):22-42
  • Notch-ing from T Cell Leukemia to Multiple Myeloma. (submitted). 2011.
  • Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. 2012
  • Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. (submitted). 2011.
  • Targeting galectin-3 unveils the complexity of multiple myeloma: a sweet context. Galectins and Disease. Implications for Targeted Therapeutics, Ed by Anatole A. klyosov and Peter G Traber (eds) 2012
  • Clinical Perspectives in Cancer Vaccines for Hematological Deseases. Cancer Vaccines, Informa Healthcare, Ed. Bot, Marincola Obrocea. 2011
  • Ethics in Biomedical Research with examples in multiple myeloma and cervical cancer vaccines. Professionalism & Ethics in a Surgical Practice. 2008
  • Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia. 2013 Jan 11
  • Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: An approach for localized thrombolysis. Thromb Res. 2012 Dec 23
  • Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol. 2012 Oct;31(5):302-20
  • Int Rev Immunol. Cancer testis antigens: a novel target in lung cancer. 2012 Oct;31(5):321-43
  • Application of vitamin D and derivatives in hematological malignancies. Cancer Lett. 2012 Jun 1;319 (1):8-22
  • Aging, cancer, and cancer vaccines. Immun Ageing. 2012 Apr 17;9(1):4
  • Chemotherapeutic sensitization of leptomycin B resistant lung cancer by pretreatment with doxorubicin. PLoS One. 2012;7(3).
  • Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk Lymphoma. 2011 Dec:52(12):2380-90
  • CKD1-mediated phosphorylation of Abi1 attenuates BCR-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. J Biol Chem. 2011 Nov 4:286(44):38614-26
  • Notch1 regulates chemtaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukemia. J Pathol. 2011 Oct 7.
  • Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. BMC Cancer. 2011 Sep 16:11:394
  • Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One. 2011:6(7):e21811.
  • Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. Doi: 10.1002/pros.21400, 2011
  • CRM1-dependent p53 nuclear accumulation in lung lesions of a bitransgenic mouse lung tumor model. Oncol Rep. doi: 10.3892/or.2011.1279, 2011
  • Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev immunol. 2011 Apri-June;30(2-3):71-86

Presentations:

  • Effect of kepivance on the incidence of mucositis, hospital stay, and total parenteral nutrition in patients undergoing stem cell transplant.SSCI Meeting. New Orleans, La. Feb 9, 2007
  • Ropporin is a novel cancer testis antigen for multiple Myeloma. SSCI Meeting. New Orleans, La. Feb 9, 2007
  • PTTG-1: an immunologic target for Multiple Myeloma. SSCI Meeting. New Orleans, La. Feb 9, 2007
  • Hematologic and renal recovery in a patient with light-chain multiple Myeloma and end-stage renal disease after two consecutive stem cell transplants.SSCI Meeting. New Orleans, La. Feb 9, 2007
  • Is AKAP-4 a novel cancer testis antigen for multiple Myeloma? SSCI Meeting. New Orleans, La. Feb 9, 2007
  • AKAP-Associated sperm protein over expression in ovarian cancer. SSCI Meeting. New Orleans, La. Feb 9, 2007.
  • Cytotoxicity and CRM1 down-regulation of 4-(methylnitro-samino)-1-(3-pyridyl)-1- butanone in human bronchial epithelial cell line. 47th Annual Meeting of Society of Toxicology, 2008. Seattle, WA. Mar 16-20.
  • Antibody Microarray Analysis of Serum Glycans in Esophageal Squamous Cell Carcinoma Cases and Controls, 2008 AACR Annual meeting. San Diego, CA. Apr 12-16, 2008.
  • Human glioma cells affect astrocyte phenothype in a co-culture experimental model. It. J. Anat Embriol. 113 (suppl. 1): 127,2008.
  • AKAP-4 as a biomarker for prostate cancer. IT. J. Anat. Embriol. 113 (suppl. 1): 77, 2008.
  • Characterization of astrocytes-glioma interaction in a co-colture experimental model. Abstract Book del XXIst Meeting of the Federation of the European Connective Tissue Societies, Marsiglia, Francia, 9-13 July 2008: 130.
  • Analysis of astrocyte-glioma interatctions in a co-culture experimental model. Southern Regional Meetings and the Southern Society for Clinical Investigation (SSCI) annual meeting, New Orleans, 21-23 Feb. 2008. J. Invest. Med. 56: 471, 2008.
  • Sperm protein 17 is expressed in primary and metastatic breast cancer. Southern Regional Meetings and the Southern Society for Clinical Investigation (SSCI) annual meeting, New Orleans, LA. Feb 21-23, 2008. J. Invest. Med. 56: 469-470, 2008.
  • AKAP-4 as biomarker for prostate cancer. Southern Regional Meetings and the Southern Society for Clinical Investigation (SSCI) annual meeting, New Orleans, LA. Feb 21-23, 2008. J. Invest. Med. 56: 394, 2008.
  • Characterization of collagen turnover pathways in human aging gingival fibroblasts. Southern Regional Meetings and the Southern Society for Clinical Investigation (SSCI) annual meeting, New Orleans, LA, Feb 21-23, 2008. J. Invest. Med. 56: 380-381, 2008.
  • Analysis of collagen turnover in healthy human gingival fibroblasts treated with different doses of tacrolimus. Southern Regional Meetings and the Southern Society for Clinical Investigation (SSCI) annual meeting, New Orleans, LA. Feb 21-23 2008. J. Invest. Med. 56: 357-358, 2008.
  • Protein in human bronchial epithelial cells exposed to 4-(methylnitro-samino)-1-(3-pyridyl)-1-butanone. 48th Annual Meeting of Society of Toxicology, 2009. Baltimore, MD. Mar 15-19, 2009.
  • Identification of autoantibodies against tumor-derived antigens as biomarkers for early detection and diagnosis of esophageal cancer. 48th Annual Meeting of Society of Toxicology, 2009. Baltimore, MD. Mar 15-19, 2009.
  • p53 nuclear accumulation and CRM1 down-regulation in lung lesions of a bitransgenic mouse lung tumor model. 2009 AACR Annual meeting. Proceedings of the American Association for Cancer Research, 2009.
  • Cytotoxicity, chromosome maintenance region 1 and nuclear proteomic effects of Leptomycin B on human normal and cancer lung cell lines. 2009 AACR Annual meeting. Proceedings of the American Association for Cancer Research, 2009.
  • Cancer Testis Antigen-Sp17 Therapeutic Vaccination Induces Protective Immune Response against ovarian cancer. International meeting for Clinical Cancer Immunotherapy & Translational Research 2009: Approaching science to patients. Oral and poster presentation. Havana, Cuba. November 19-21, 2009.
  • Sperm protein 17 Vaccination Induces a Long-term Protective Immune Response against ovarian cancer. International Society for Biological Therapy of Cancer. Poster presentation (ID: 684069) iSBTc. Poster presentation. 24th Annual Meeting. Washington. USA. October 29-31, 2009.
  • In Vitro Evolution of Leptomycin B Cytotoxic Effects of Lung Cancer Cells. Annual meeting of Society of Toxicology. Salt Lake City, UT. March 11, 2010.
  • The Alterations of P53 Protein Phosphorylation and Ribosylation in Human Bronchial Epithelial Cells Exposed to 4-(Methylnitro-Samino)-1-(3-Pyridyl)-1-Butanone. Annual meeting of Society of Toxicology. Salt Lake City, UT. March 11, 2010.
  • Effective prevention and therapy of ovarian cancer with sperm protein 17 vaccination. 97th. Annual meeting of the American Association of Immunologists. Baltimore, MD. May, 2010.
  • Sp17 Protein with CpG Immunization Induces an Active Immune Response Against Ovarian Cancer in the ID8 Animal Model. Vaccine Third Global Congress, Singapore. October, 2009.
  • Sperm protein 17 vaccination induces a long-term protective immune response against ovarian cancer. 24th Annual meeting of the International Society for Biological Therapy of Cancer, Washington, DC, October 2009.
  • Dendritic cell redirection of regulatory T cell responses to ovarian cancer antigens. 24th Annual meeting of the International Society for Biological Therapy of Cancer, Washington, DC. October 2009.
  • PARADIGM SHIFT IN OVARIAN CANCER IMMUNOTHERAPY: BREAKING IMMUNE TOLERANCE REDIRECTING T-HELPER DIFFERENTIATION WITH CANCER/TESTIS ANTIGEN VACCINATION. International Society for Biological Therapy of Cancer's (iSBTc) 25th Annual Meeting, October 2-4, 2010, Washington, D.C. Abstract ID number: 913825
  • Novel tumor markers in non-small cell lung cancer detected both in serology and tissue. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e21105)
  • Effect of PEDF on survival and in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e15103)
  • Effect of PEDF on survival and the in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer. 2012 Genitourinary Cancers Symposium. J Clin Oncol 30, 2012 (suppl 5; abstr 237)
  • (2012). The cancer/testis antigens Ropporin and AKAP-4 are novel targets for multiple myeloma immunotherapy. SITC 27th Annual Meeting, North Bethesda, MD. October 26-28.
  • (2012). Multiple Myeloma Biomarker Variation between Genders. 3nd Annual CPRIT Innovations in Cancer Prevention and Research Conference. Austin Convention Center. Austin, TX. Oct 24-26.
  • Effect of PEDF on survival and the in vivo antitumor activities of low-dose chemotherapy in castration-refractory prostate cancer. 2012 Genitourinary Cancers Symposium February 2-4, 2012 San Francisco, CA. Abstract ID number 89531.
  • (2011). Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. TTU/TTUHSC Post-doc day on April 22nd 2011 at the International Cultural Center TTU/TTUHSC, Lubbock, TX. April 22. (*won poster presentation 3rd place - prize $500)
  • (2011). New antigens in non-small cell lung cancer detected both in serology and tissue. 2nd Annual CPRIT Innovations in Cancer Prevention and Research Conference. Austin Convention Center. Austin, TX. November 15-17.
  • Identification of new cancer/testis antigens in non-small cell lung cancer. TTUHSC-Research Week, 2011. Junior Basic Science- March 2, 2011. (*won poster presentation 3rd place - prize $300)
  • (2011). Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. 2nd Annual CPRIT Innovations in Cancer Prevention and Research Conference. Austin Convention Center. Austin, TX. November 15-17.
  • “Notch1 produces a deregulation of CXCR4/SDF1 chemokine signaling in multiple myeloma cells”. Immunology 2011 Meeting Abstract on The Journal of Immunology, 2011, 186, 149.12
  • Notch1 produces a deregulation of chemokine receptors expression and functions in hematological tumors. Accettato per la presentazione come poster al 1st World Congress on Controversies in Hematology (COHEM), Rome, Italy, 2-5 September, 2010.
  • (2011). New Antigens in Non-small Cell Lung Cancer Detected both in Serology and Tissue. Lung Cancer: Predictors and Diagnosis CHEST National Meeting. Hawaii, October, 24. (*selected for an oral presentation)
  Research Interests  

No research information available online at this time.